| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1044273088 |
| P356 | DOI | 10.1007/S10555-013-9476-Y |
| P698 | PubMed publication ID | 24390423 |
| P50 | author | Kenneth J. Pienta | Q6390246 |
| Daniel F Camacho | Q56560819 | ||
| P2860 | cites work | The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis | Q21093318 |
| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer | Q24632187 | ||
| Sipuleucel-T immunotherapy for castration-resistant prostate cancer | Q27860648 | ||
| CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases | Q28278260 | ||
| CXCR4 regulates growth of both primary and metastatic breast cancer | Q28296113 | ||
| Disrupting the networks of cancer | Q28656016 | ||
| The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited | Q29547915 | ||
| Distinct role of macrophages in different tumor microenvironments | Q29614304 | ||
| Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 | ||
| The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies | Q29614311 | ||
| Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis | Q29620559 | ||
| A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone | Q31045889 | ||
| Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. | Q31144457 | ||
| Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial | Q32040849 | ||
| Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer | Q33280211 | ||
| Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma | Q33376008 | ||
| Lenalidomide in the treatment of multiple myeloma | Q33376390 | ||
| Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease | Q33405335 | ||
| Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial | Q33946929 | ||
| Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review. | Q33991574 | ||
| Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer | Q33997362 | ||
| Novel therapies for metastatic castrate-resistant prostate cancer | Q34249263 | ||
| Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer | Q34295041 | ||
| Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells | Q40221505 | ||
| Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. | Q40453891 | ||
| Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. | Q40472142 | ||
| Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours | Q40592751 | ||
| G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. | Q40724468 | ||
| Angiogenesis and tumor metastasis | Q41724143 | ||
| Annexin II expressed by osteoblasts and endothelial cells regulates stem cell adhesion, homing, and engraftment following transplantation | Q42219222 | ||
| The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo | Q43131941 | ||
| Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer | Q44918129 | ||
| Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials | Q45261093 | ||
| Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer | Q46108775 | ||
| Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma | Q46712881 | ||
| Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. | Q46842240 | ||
| Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 | ||
| PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. | Q53255741 | ||
| Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial | Q56897633 | ||
| Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma | Q57904843 | ||
| A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. | Q34326476 | ||
| Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow | Q34755120 | ||
| Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors | Q35197931 | ||
| Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy. | Q35582297 | ||
| Clinical development of anti-RANKL therapy | Q35901092 | ||
| CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration | Q35925135 | ||
| Molecular insights into prostate cancer progression: the missing link of tumor microenvironment | Q35980774 | ||
| Proteasome inhibitor therapy in multiple myeloma | Q36096768 | ||
| The "emigration, migration, and immigration"of prostate cancer | Q36181524 | ||
| Extracellular matrix in bone marrow can mediate drug resistance in myeloma | Q36194659 | ||
| Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype | Q36309713 | ||
| Integrins: molecular targets in cancer therapy | Q36409214 | ||
| Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy | Q36414978 | ||
| Role of tumor-associated macrophages in tumor progression and invasion | Q36591374 | ||
| Monocyte/macrophage infiltration in tumors: modulators of angiogenesis | Q36602360 | ||
| Meta-analysis of clodronate and breast cancer survival | Q36609657 | ||
| Sipuleucel-T (APC8015) for prostate cancer | Q36613961 | ||
| Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. | Q36616704 | ||
| Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis | Q36633811 | ||
| Future treatment of bone metastases | Q36633827 | ||
| The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis | Q36682096 | ||
| Modification of the tumor microenvironment to enhance immunity | Q36813796 | ||
| Sorafenib: delivering a targeted drug to the right targets | Q36817095 | ||
| The use of bisphosphonates in cancer patients | Q36846894 | ||
| Tumor promotion by tumor-associated macrophages | Q36908944 | ||
| Bortezomib for the treatment of mantle cell lymphoma | Q36944390 | ||
| The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance | Q37152481 | ||
| Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines | Q37181792 | ||
| Denosumab for bone diseases: translating bone biology into targeted therapy. | Q37919678 | ||
| The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer | Q37944154 | ||
| Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date | Q38068203 | ||
| 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma | Q39339046 | ||
| Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. | Q39457367 | ||
| Cellular interactions in the tropism of prostate cancer to bone | Q39462075 | ||
| Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection | Q40164471 | ||
| Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin | Q40195731 | ||
| P433 | issue | 2-3 | |
| P304 | page(s) | 545-553 | |
| P577 | publication date | 2014-09-01 | |
| P1433 | published in | Cancer and Metastasis Reviews | Q2647982 |
| P1476 | title | A multi-targeted approach to treating bone metastases | |
| P478 | volume | 33 |
| Q38266461 | Current studies of acupuncture in cancer-induced bone pain animal models |
| Q55209354 | Evolution: Back to the future to understand and control prostate cancer. |
| Q55387471 | Role of key players in paradigm shifts of prostate cancer bone metastasis. |
| Q58547311 | Targeting macrophages: therapeutic approaches in cancer |
| Q35181099 | The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. |
| Q38230880 | Tumor-associated macrophages: from mechanisms to therapy |
Search more.